Earthly creatures: Top picks in non-fiction for kids
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
21 minutes ago
- Yahoo
Exclusive-China's Sciwind is in talks to license weight-loss drug in US, CEO says
By Andrew Silver HANGZHOU (Reuters) -China's Sciwind Biosciences is in talks with a U.S. company interested in licensing its experimental weight-loss drug for American patients, the drugmaker's chief executive told Reuters. Overweight patients treated with Sciwind's ecnoglutide drug lost an average of 10% to 15% of their body weight, roughly in line with results from Novo Nordisk's top-selling obesity treatment Wegovy, according to a late-stage study published in medical journal The Lancet Diabetes & Endocrinology in June. 'We also hope we are able to successfully license out, and they will apply for approval in the U.S.,' Sciwind Biosciences CEO Pan Hai said, declining to identify the firm or disclose financial terms under discussion. Reuters is the first to report on the potential U.S. licensing deal. Pan said its potential partner hoped to gain U.S. marketing approval to prescribe ecnoglutide for multiple medical conditions and would carry out further clinical development. The talks are not yet at the stage of discussing a detailed contract, he added. Sciwind is hoping the partner could use clinical data accumulated in China and Australia to accelerate the development. Pan expects it would take at least three years for a U.S. partner to bring Sciwind's drug to market in the United States, and said the FDA might require a bridging study to compare ecnoglutide's pharmacokinetics - how it moves through the body - among different patient populations. Ecnoglutide is administered as a once-weekly injection. It belongs to a class of drugs called GLP-1 receptor agonists, which work by helping control blood sugar levels and triggering a feeling of fullness. Novo's Wegovy and Eli Lilly and Co's Zepbound lead the U.S. market for weight-loss drugs, but their relatively high prices leave room for new competitors to offer cheaper alternatives. Sciwind has applied to sell ecnoglutide in China for weight management and the treatment of type II diabetes. Other approved weight loss medicines in China also include drugs from Novo, Lilly and other drugmakers. Pan said he could not give an estimated time of approval. The company is also in talks to license the drug to partners for other markets, including in Latin America and the Middle East. Pricing in China would be in line with other approved competitors, Pan said, adding the company would not engage in a "price war" there. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
21 minutes ago
- Yahoo
Padres come into matchup against the Cardinals on losing streak
San Diego Padres (55-48, second in the NL West) vs. St. Louis Cardinals (53-51, fourth in the NL Central) St. Louis; Friday, 7:15 p.m. EDT PITCHING PROBABLES: Padres: Nick Pivetta (10-2, 2.81 ERA, 1.00 WHIP, 127 strikeouts); Cardinals: Miles Mikolas (5-7, 5.20 ERA, 1.30 WHIP, 69 strikeouts) BETMGM SPORTSBOOK LINE: Padres -140, Cardinals +117; over/under is 8 1/2 runs BOTTOM LINE: The San Diego Padres look to end their three-game losing streak with a win against the St. Louis Cardinals. St. Louis has a 53-51 record overall and a 30-20 record in home games. The Cardinals have a 24-6 record in games when they hit at least two home runs. San Diego has a 55-48 record overall and a 24-30 record on the road. The Padres have a 30-9 record in games when they did not give up a home run. The teams meet Friday for the second time this season. TOP PERFORMERS: Alec Burleson has 18 doubles, 12 home runs and 44 RBIs for the Cardinals. Willson Contreras is 13 for 40 with six doubles and two home runs over the past 10 games. Manny Machado has 24 doubles, 19 home runs and 63 RBIs for the Padres. Jackson Merrill is 9 for 35 with two doubles, two home runs and seven RBIs over the past 10 games. LAST 10 GAMES: Cardinals: 3-7, .269 batting average, 5.82 ERA, outscored by 20 runs Padres: 5-5, .254 batting average, 3.14 ERA, outscored opponents by nine runs INJURIES: Cardinals: Nolan Gorman: 10-Day IL (back), Lars Nootbaar: 10-Day IL (ribs), Zack Thompson: 60-Day IL (lat) Padres: Michael King: 60-Day IL (shoulder), Jhony Brito: 60-Day IL (forearm), Joe Musgrove: 60-Day IL (elbow) ___ The Associated Press created this story using technology provided by Data Skrive and data from Sportradar. The Associated Press
Yahoo
21 minutes ago
- Yahoo
Smilegate to Launch New MMORPG "LORDNINE: INFINITE CLASS" on July 31 - Pre-download Begins July 29
Pre-download available for PC and mobile on the 29th, with official launch on the 31st Proven success in Korea, LORDNINE stands out for its extensive freedom and strategic combat. SEOUL, South Korea, July 25, 2025 /PRNewswire/ -- Global game developer and publisher Smilegate announced today (Friday) that its new MMORPG "LORDNINE: INFINITE CLASS" (developed by NX3GAMES) will officially launch on July 31st, with pre-download available starting on July 29th for both PC and mobile platforms. Mobile users can pre-download LORDNINE via the App Store and Google Play, while PC users can do so through the STOVE platform. Players who pre-download the game will be able to start playing on the official launch day, the 31st, through their mobile devices or the STOVE launcher. Details such as launch time will be announced later through official channels. Following the early closure of the Character Name Reservation event, which began on the 14th, Smilegate extended the event period and expanded its servers, further heightening anticipation. On the 20th, a live showcase was held in Thailand, where key game systems and development philosophy were introduced. Popular Thai actor Peach Pachara was also revealed as the game's official global model, generating an enthusiastic response. The live showcase video is available on LORDNINE's official YouTube channel. LORDNINE features an "Infinite Class" system that allows players to freely combine over 60 classes and more than 50 abilities to design their own characters. Players can define their own combat style and character progression, enjoying a high level of freedom and strategic depth. To enrich player interaction across global servers, Smilegate has partnered with LINE's C2C trading platform, Next Market, integrating a global marketplace system into LORDNINE. This enables players worldwide to safely trade items and engage in cross-server economic activities. Since its release in Korea and Taiwan region in July last year, LORDNINE has continued to gain popularity. In Korea, the game topped revenue charts in the RPG category across both major marketplaces and was awarded "Best Immersive MMORPG" at the SensorTower APAC Awards 2024, earning recognition for both its quality and commercial success. More information about the event and the game can be found on the official LORDNINE website ( and YouTube channel ( About Smilegate Smilegate is a global game development and publishing company headquartered in South Korea, with regional offices in the United States and China. Its flagship franchise 'CROSSFIRE,' is one of the largest and most successful franchises in gaming history. It has more than 1 billion registered players to date in PC and mobile platforms and over 8 million concurrent players globally. Its acclaimed MMORPG Lost Ark was released in South Korea in 2019 and launched in North America and Europe in February 2021. Learn more by visiting View original content to download multimedia: SOURCE Smilegate Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
